Today: 7 February 2026
Subscribe

Mateusz Kaczmarek

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

AlphaVest (ATMV) Rockets on AMC Robotics Merger Buzz – Key Facts & Forecast

AlphaVest (ATMV) Rockets on AMC Robotics Merger Buzz – Key Facts & Forecast

SPAC Structure and Acquisition Target AlphaVest Acquisition Corp is a special-purpose acquisition company (SPAC) – a “blank check” issuer that raised capital through an IPO to merge with a private company stockanalysis.com globenewswire.com. It has no business operations of its own; its entire asset is cash held in a trust. SPAC shareholders typically get stock in the merged company or can redeem their shares for cash (the trust value) if the deal fails. AlphaVest’s announced target is AMC Corporation, a Washington-based technology company specializing in AI-driven security and safety solutions marketscreener.com. AMC has developed products like YI-brand smart cameras and
21 October 2025
·····
RTX Stock Skyrockets: Aerospace & Defense Boom Sends Q3 Results and 2025 Forecast Soaring

RTX Stock Skyrockets: Aerospace & Defense Boom Sends Q3 Results and 2025 Forecast Soaring

Blowout Q3 Earnings On Oct. 21, RTX reported a blowout quarter. Total sales jumped 12% year-over-year to $22.48 billion globalbankingandfinance.com, handily above the ~$21.3B Wall Street estimate. Adjusted earnings came in at $1.70 per share, well above the consensus ~$1.41 globalbankingandfinance.com investing.com. The results were driven by strength across its portfolio: Collins Aerospace revenues hit $7.62B (+8%), and Pratt & Whitney engine sales rose 16% to $8.42B (boosted by surging Airbus A320neo orders) globalbankingandfinance.com. RTX’s defense unit (legacy Raytheon) reported a 10% jump in sales, “predominantly from higher sales for its Patriot air defense systems” being used in Ukraine globalbankingandfinance.com.
21 October 2025
·
Apple’s iPhone 17 BOOM: Sales Surge, Stock Soars Near $4T – What Analysts Say

Apple’s iPhone 17 BOOM: Sales Surge, Stock Soars Near $4T – What Analysts Say

Apple Inc. (NASDAQ: AAPL) is riding high on the strength of its new iPhone 17. Counterpoint Research data show the iPhone 17 line (launched in September) outsold the iPhone 16 series by 14% in their first 10 days on the U.S. and Chinese markets reuters.com investing.com. In particular, the entry-level iPhone 17 has been a smash hit – Chinese demand for the basic model nearly doubled versus last year cnnbrasil.com.br investing.com. Counterpoint senior analyst Mengmeng Zhang credits its “excellent cost-benefit” and strong specs (new A19 chip, bigger screen and storage) at the same price as 2024 investing.com. As one consumer note, Apple even
21 October 2025
···
Valletta Goes Green: MSC Cruises Powers Up Emission-Free Port Calls

Valletta Goes Green: MSC Cruises Powers Up Emission-Free Port Calls

MSC’s Shore-Power Milestone in Valletta During Malta’s GreenPort Congress (Oct 15–17, 2025), MSC Cruises held a ceremony celebrating two ships plugging into the new high-voltage shore-power lines at Valletta’s Grand Harbour. On Oct 15 MSC World Europa (a 205,700 GT LNG-powered mega-ship) connected to the grid, and on Oct 16 EXPLORA II (MSC’s luxury Explora brand) did the same mscpressarea.com crew-center.com. This is the first time MSC has achieved consecutive-day shore-power hookups, and makes Explora II the first vessel of its brand to use shoreside electricity in Europe mscpressarea.com crew-center.com. MSC reports its ships have now used Valletta’s shore power
21 October 2025
Lockheed Martin Stock Soars on Earnings Beat – “We’re an arm of the U.S. government,” analyst quips

Lockheed Martin Stock Soars on Earnings Beat – “We’re an arm of the U.S. government,” analyst quips

Robust Q3 Results and Increased Guidance Lockheed Martin’s (NYSE:LMT) Oct. 21 earnings release blew past forecasts, reflecting surging military demand. Revenue rose 8.8% year-over-year to $18.61 billion and net income was $6.95/share seattlepi.com. That beat Wall Street’s $6.33/share estimate and matched analyst forecasts of about $18.56 billion. CEO Jim Taiclet highlighted the “unprecedented demand” for Lockheed products, noting a record $179 billion backlog – over 2½ years of sales news.lockheedmartin.com. In light of the strong quarter, Lockheed raised 2025 guidance. It now expects $22.15–$22.35 EPS (vs prior $21.70–$22.00) and about $74.25–$74.75 billion in revenue reuters.com. Jim Taiclet emphasized the scale of current demand: “Based
21 October 2025
··
Coca-Cola Crushes Q3 Forecasts as Soda Sales Stay Hot – Stock Jumps

Coca-Cola Crushes Q3 Forecasts as Soda Sales Stay Hot – Stock Jumps

Strong Q3 Performance Beats Estimates Coca-Cola’s (NYSE: KO) Q3 2025 report blew past Wall Street’s forecasts. The beverage giant logged $12.5 billion in revenue, up 5% from last year (organic sales +6%) stocktitan.net. This exceeded the ~$12.39 billion consensus reuters.com. Volume was flat to slightly positive (+1%), but robust price/mix (+6%) drove growth. As a result, EPS of $0.86 surged 30% year-over-year stocktitan.net, topping the $0.78 street estimate reuters.com by 4 cents. Even excluding special items, Coke’s adjusted EPS of $0.82 comfortably beat forecasts. Notably, operating profit jumped 59% (29% currency-neutral) with an operating margin of 32.0% (vs 21.2% a year ago)
21 October 2025
Kraken Lists ASTER: Is This New DeFi Token the Next Big Thing?

Kraken Lists ASTER: Is This New DeFi Token the Next Big Thing?

A deeper look shows Kraken’s move brings a sophisticated DeFi token to its exchange. According to Kraken, ASTER is “a next-gen decentralized exchange offering spot and perpetual trading” across multiple chains blog.kraken.com. Its technology includes MEV-free execution and on-chain perpetuals (even a 1,001x leverage mode) with innovative collateral features blog.kraken.com binance.com. In practice, Aster lets traders earn yield on collateral like liquid-staked BNB (asBNB) and use a native stablecoin (USDF) to improve capital efficiency blog.kraken.com. (Binance Academy explains Aster uses advanced zero-knowledge proofs to protect trades from front-running and allow assets to earn yield as collateral binance.com.) In early October
21 October 2025
·
Lynas Rare Earths (LYSCF) Stock Soars on $8.5B U.S.–Australia Rare-Earth Pact

Lynas Rare Earths (LYSCF) Stock Soars on $8.5B U.S.–Australia Rare-Earth Pact

Full Story: Below we examine Lynas Rare Earths’ recent news flow, stock trends, growth plans, and expert analysis in detail. Stock Performance & Recent Trend Lynas shares have been on a tear. By mid-October 2025, the stock (ASX: LYC) had nearly tripled in a year (from ≈A$6 in late 2024 to ~$19) Investing ts2.tech. In early October it spiked to A$21.96 (its highest since 2011) Investing on the magnet-chain MoU, then eased back to ~$18–19 as traders locked in profits ts2.tech. In late Oct 20–21 trading it jumped again (+15% on Oct 20) Stockanalysis. By Oct 21 LYC was ~A$19 (US$14) Investing
21 October 2025
··
Alcoa (AA) Stock Poised for Breakout? Gallium Project, Tariff Relief & $40 Target Stun Investors

Alcoa (AA) Stock Poised for Breakout? Gallium Project, Tariff Relief & $40 Target Stun Investors

Alcoa’s stock story is a mix of bullish projects and market risks. The recent government-backed gallium plant (critical mineral for tech and defense) is a major positive, potentially diversifying Alcoa’s business beyond aluminium. Yet the industry is grappling with high US tariffs and costs. Below we break down these developments and what analysts are saying. Government support and the new Gallium project On Oct. 20, Alcoa announced that US and Australian agencies will provide funding for a joint venture to build a gallium plant at Alcoa’s Wagerup alumina refinery in Western Australia news.alcoa.com. In August Alcoa and a Japanese-US-Australian venture
21 October 2025
·
Stratasys (SSYS) Stock Surges 14%: Why 3D Printing Shares Are Heating Up

Stratasys (SSYS) Stock Surges 14%: Why 3D Printing Shares Are Heating Up

In summary, Stratasys’s stock has surged to multi-month highs on a combination of company-specific catalysts and broader market tailwinds. Recent acquisitions (Forward AM, Nexa3D), strategic partnerships (e.g. Toyota), and solid quarterly results have helped offset lingering macro uncertainty. Analysts remain cautious (average price targets near $13), but insiders emphasize that the core additive-manufacturing trend remains intact 3dprint.com investors.stratasys.com. With the U.S. manufacturing cycle poised for recovery and Fed policy possibly loosening, many experts see potential upside for SSYS in late 2025 and beyond – though they warn that customer spending could stay restrained until the economy stabilizes finviz.com investors.stratasys.com. Sources:
21 October 2025
HeartCore (HTCR) Stock Soars on Dividend Surprise – Analysts Weigh In

HeartCore (HTCR) Stock Soars on Dividend Surprise – Analysts Weigh In

Stock Performance & Dividend Announcement HTCR’s stock surged on Oct. 20, 2025, when the company revealed the $0.13/share dividend globenewswire.com. In after-hours trading, the share price jumped roughly 40% investing.com. (According to Investing.com, HeartCore stock “surged 40% in after-hours trading on Monday” after the dividend news investing.com.) By Oct. 21, HTCR traded around $0.71 reuters.com. The stock’s 52-week range is $0.39–$3.38 stockanalysis.com, reflecting swings earlier this year (it spiked above $3 in early 2025 before retreating). The dividend announcement itself was a headline event. In a GlobeNewswire release on Oct. 20, HeartCore said the one-time $0.13 payment represents ~17.8% of
21 October 2025
·
Beam Therapeutics Stock Soars on FDA Backing – Analysts Forecast ~70% Upside

Beam Therapeutics Stock Soars on FDA Backing – Analysts Forecast ~70% Upside

Ticker: Beam Therapeutics (NASDAQ: BEAM) globenewswire.com. – Price (Oct 21, 2025): ~$30 per share (about +17% recently) ts2.tech. – Sector: Biotechnology (precision gene editing) globenewswire.com. – Recent News: FDA granted Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug designations to Beam’s lead programs (BEAM-101 for sickle cell disease and BEAM-302 for alpha-1 antitrypsin deficiency) globenewswire.com stocktitan.net. Early trial data for these programs have been promising. – Analyst Outlook: Consensus is “Moderate Buy” with average 1-year target ~$45–46 marketbeat.com nasdaq.com, implying roughly 70–80% upside. Beam’s stock jumped sharply after the FDA awarded priority designations to its gene-editing therapies. On Oct 20,
21 October 2025
··
DocGo (NASDAQ: DCGO) Stock Rockets After Virtual Care Acquisition – Can the Rally Last?

DocGo (NASDAQ: DCGO) Stock Rockets After Virtual Care Acquisition – Can the Rally Last?

Stock Surges on SteadyMD Acquisition DocGo’s shares jumped more than 34% in after-hours trading on Oct. 20, 2025, after the company announced it would acquire SteadyMD, a virtual care platform. According to an Investing.com report, DocGo stock “surged 34.6% in after-hours trading Monday following the company’s announcement that it has acquired virtual care platform SteadyMD” m.uk.investing.com. The acquisition was disclosed on Monday, Oct. 20, and a conference call to discuss it was scheduled for Oct. 21. SteadyMD brings a nationwide telehealth network (600+ clinicians serving ~3 million patients in 2025) to DocGo’s existing mobile health and ambulance services citybiz.co m.uk.investing.com.
21 October 2025
SPRO Stock Skyrockets on Breakthrough Oral Antibiotic Data

SPRO Stock Skyrockets on Breakthrough Oral Antibiotic Data

Stock Performance stockanalysis.com stockanalysis.com Spero’s shares have roughly doubled this year, hitting around $2.29 on Oct 20, 2025. The stock has traded in a broad range ($0.51–$3.22 over 52 weeks) stockanalysis.com. Trading volume is light (hundreds of thousands of shares), and the stock’s beta (~1.46) indicates volatility. In recent days, SPRO has climbed on the back of the Phase 3 data. The 50-day moving average (~$2.03) and 200-day average (~$1.83) (see data marketbeat.com) suggest the trend has turned positive after the spring rally. Year-to-date, SPRO is up ~120%, well above the small-cap biotech average. Recent Developments gsk.com gsk.com At IDWeek
21 October 2025
··
Replimune Stock Rockets 100% on FDA Nod – Analysts Eye Upside

Replimune Stock Rockets 100% on FDA Nod – Analysts Eye Upside

Stock Performance and Recent Rally Replimune’s stock has been extremely volatile in 2025. It soared on Oct. 20 after the FDA acceptance news: shares nearly doubled from about $4.50 to $8.94 that day marketbeat.com. (On Oct 21, REPL was trading around $8.95 reuters.com.) This reversed a mid-year collapse – in July 2025 a disappointing FDA Complete Response Letter caused the stock to collapse ~73% in one day globenewswire.com. Over the past year the 52-week trading range is roughly $2.68 (low) to $17.00 (high) marketbeat.com, reflecting that roller-coaster. Institutional interest remains high: recently hedge funds like TD Asset Management increased their
21 October 2025
·
Beyond Meat (BYND) Stock Skyrockets 50% Amid Meme Mania – Turnaround or Dead Cat Bounce?

Beyond Meat (BYND) Stock Skyrockets 50% Amid Meme Mania – Turnaround or Dead Cat Bounce?

Volatile Stock Action Chart: Beyond Meat (BYND) daily price (1y) via TradingView – after years of decline, BYND plunged to fresh lows in mid-October then briefly spiked amid heavy short covering (note the October jump). fxleaders.com businessinsider.comOver the past week BYND has lived up to its volatile reputation. On Oct. 13–15 the stock collapsed roughly 50–60% as news of the debt-for-equity swap (to repay over $1.1 B of 2027 convertible notes) sank in reuters.com ts2.tech. By Oct. 15 it traded around $0.67 ts2.tech, an all-time low. But the tide quickly turned: in pre-market trading on Oct. 20 the stock jumped ~70% from $0.64
21 October 2025
Netflix Stock Soars: Wall Street Targets $1,500 as Earnings Loom

Netflix Stock Soars: Wall Street Targets $1,500 as Earnings Loom

Macroeconomic Backdrop Investors also consider the broader economy. After a year of volatility, the U.S. Federal Reserve began easing in 2025. By mid-October, the Fed’s benchmark rate was 4.00–4.25% investopedia.com. Economists say Fed officials are trying to gently “take the foot off the brake” on policy to avoid a sharp slowdown investopedia.com. In this environment (lower rates, contained inflation), stocks like Netflix have generally been supported. As one analyst notes, Netflix’s recent gains occurred “in a favorable macroeconomic context, with expectations of monetary easing in the U.S. and relative stability in bond markets” ideal-investisseur.fr. However, rising U.S.–China trade tensions and
21 October 2025
·
Cleveland-Cliffs Stock Rockets on Tariffs and Rare-Earth Push – But Caution Remains

Cleveland-Cliffs Stock Rockets on Tariffs and Rare-Earth Push – But Caution Remains

Stock Price and Recent Movement On Oct. 20, CLF stock surged after-market, reflecting the earnings and strategic announcements. TS2 reports the stock “jumped nearly 20% on October 20, 2025”, reaching an intraday high around $16.50 before settling at about $15.50 ts2.tech. This lifted the share price to a new 52-week high and brought the year-to-date gain to roughly +42% ts2.tech ts2.tech. For comparison, U.S. steel peers like Nucor saw much smaller moves; Nucor’s stock was up ~17% YTD and edged up modestly in late Oct, while CLF jumped sharply ts2.tech. Broad market action was relatively stable on Oct. 20, suggesting CLF’s
21 October 2025
AI Chip Breakthrough Sends GSI Technology (GSIT) Stock Soaring 200% – What Investors Need to Know

AI Chip Breakthrough Sends GSI Technology (GSIT) Stock Soaring 200% – What Investors Need to Know

Cornell Validation Spurs Stock Rally On Oct 20, a Cornell University-led study (MICRO ’25 conference) confirmed that GSI’s Gemini‑I APU can deliver GPU-like AI performance using far less power investing.com economictimes.indiatimes.com. In benchmarks on large retrieval-augmented generation (RAG) workloads, GSI’s chip achieved throughput comparable to an NVIDIA A6000 GPU while using ~98% less energy investing.com economictimes.indiatimes.com. The study also found the APU ran RAG tasks several times faster than standard CPUs (up to 5× speedup or ~80% shorter processing time) investing.com ts2.tech. GSI CEO Lee-Lean Shu hailed the independent validation, saying “Cornell’s independent validation confirms what we’ve long believed –
21 October 2025
··
1 … 68 69 70 71 72 … 140

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop